Home / CLRB : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does CLRB make money? Does CLRB have pricing power? What's the Earnings Whisper? Will CLRB profit more as the business scales? What is CLRB's management track record? Is CLRB's current price justified?

Cellectar Biosciences, Inc.

$2.31 -$1.16 (-33.43%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$2.37

Day Range

$2.31$2.38

Year Range

$2.2$6.52

Market Cap

18.46M

AVG Volume

1.07M

Trailing/Forward PE

-0.51/-

PEG ratio

0.02

Dividend Yield

Next Earnings Date

2026-11-12

Primary Exchange

NASDAQ

Net Income (USD)

CLRB Net Income (USD) by year
Period	Net Income (USD)
2025	-21.79M
2024	-44.58M
2023	-42.77M
2022	-33.79M
2021	-24.12M
2020	-15.09M
2019	-14.09M
2018	-13.24M
2017	-13.56M
2016	-6.18M

Operating Income (USD)

CLRB Operating Income (USD) by year
Period	Operating Income (USD)
2025	-22.98M
2024	-51.78M
2023	-38.96M
2022	-28.81M
2021	-24.13M
2020	-15.29M
2019	-14.18M
2018	-13.33M
2017	-13.6M
2016	-9.45M

EBITDA (USD)

CLRB EBITDA (USD) by year
Period	EBITDA (USD)
2025	-21.58M
2024	-44.22M
2023	-42.64M
2022	-33.7M
2021	-23.97M
2020	-15.15M
2019	-14.05M
2018	-11.57M
2017	-12.05M
2016	-9.09M

Cash Flows (USD)

CLRB Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-23.12M
2024	-47.69M
2023	-33.24M
2022	-25.45M
2021	-22.71M
2020	-14M
2019	-11.72M
2018	-11.83M
2017	-11.37M
2016	-8.35M

EPS (USD)

CLRB EPS (USD) by year
Period	EPS (USD)
2025	-10.35
2024	-45.53
2023	-104.92
2022	-145
2021	-132.11
2020	-273.42
2019	-597.73
2018	-1874.81
2017	-2520.07
2016	-116.93

Expenses (USD)

CLRB Expenses (USD) by year
Period	Expenses (USD)
2025	22.99M
2024	51.88M
2023	39.82M
2022	29.04M
2021	24.27M
2020	15.35M
2019	14.2M
2018	12.04M
2017	13.95M
2016	9.52M

Cash & Debt (USD)

CLRB Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	13.2M
2024	23.29M
2023	9.56M
2022	19.87M
2021	35.7M
2020	57.17M
2019	10.61M
2018	13.26M
2017	10.01M
2016	11.44M

Debt ratios

CLRB Debt ratios by year
Period	Debt ratios
2025	0.09
2024	0.16
2023	0.08
2022	0.22
2021	0.55
2020	1.07
2019	0.22
2018	0.32

Return on Capital

CLRB Return on Capital by year
Period	Return on Capital
2025	-219.69%
2024	-311.87%
2023	310.45%
2022	-354.4%
2021	-73%
2020	-27.55%
2019	-155.56%
2018	-99.83%
2017	-126.11%
2016	-45.65%

Shares Outstanding

CLRB Shares Outstanding by year
Period	Shares Outstanding
2025	4.24M
2024	1.4M
2023	647.37K
2022	310.2K
2021	203.67K
2020	151.47K
2019	31.29K
2018	15.77K
2017	5.42K
2016	103.68K

Book Value Per Share (USD)

CLRB Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	2.34
2024	10.23
2023	-21.28
2022	30.74
2021	162.25
2020	361.74
2019	289.55
2018	840.68
2017	1984.58
2016	130.59

Total Assets (USD)

CLRB Total Assets (USD) by year
Period	Total Assets (USD)
2025	14.98M
2024	25.47M
2023	12.08M
2022	21.59M
2021	37.2M
2020	58.66M
2019	12.25M
2018	15.05M
2017	12.87M
2016	15.32M

Employee Count

CLRB Employee Count by year
Period	Employee Count
2025	11
2024	11
2023	20
2022	15
2021	12
2020	11
2019	8
2018	7
2017	15
2016	15

Free Cash Flow Yield

CLRB Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-68.96%
Sep 26	-67.21%
Aug 26	-62.96%
Aug 26	-61.5%
Aug 26	-61.27%
Aug 26	-170.59%
Jul 26	-170.59%
Jul 26	-181.92%
Jul 26	-174.67%
Jul 26	-155.47%
Jul 26	-156.02%
Jun 26	-173.98%
Jun 26	-157.14%
Jun 26	-196.6%
Jun 26	-169.27%
May 26	-139.62%
May 26	-137.01%
May 26	-141.88%
May 26	-175.92%
May 26	-202.74%
Apr 26	-197.6%
Apr 26	-186.77%
Apr 26	-197.6%
Apr 26	-213.87%
Mar 26	-201.99%
Mar 26	-168.32%
Mar 26	-170.43%
Mar 26	-197.6%
Feb 26	-289.48%
Feb 26	-278.35%
Feb 26	-285.96%
Feb 26	-309.48%
Jan 26	-292.18%
Jan 26	-248.24%
Jan 26	-262.06%
Jan 26	-305.46%
Jan 26	-271.13%
Dec 25	-367.5%
Dec 25	-351.05%
Dec 25	-259.89%
Dec 25	-249.55%
Nov 25	-262.06%
Nov 25	-328.96%
Nov 25	-324.42%
Nov 25	-635.16%
Oct 25	-635.16%
Oct 25	-538.3%
Oct 25	-478.49%
Oct 25	-464.05%
Oct 25	-372.53%
Sep 25	-390.07%
Sep 25	-414.08%
Sep 25	-423.86%
Sep 25	-432.37%
Aug 25	-442.13%
Aug 25	-441.23%
Aug 25	-496.13%
Aug 25	-601.32%
Aug 25	-602.59%
Jul 25	-558.79%
Jul 25	-569.99%
Jul 25	-582.84%
Jul 25	-592.55%
Jun 25	-360.03%
Jun 25	-325.06%
Jun 25	-229.37%
Jun 25	-262.87%
May 25	-371.8%
May 25	-380.75%
May 25	-386.97%
May 25	-460.05%
May 25	-420.39%
Apr 25	-367.05%
Apr 25	-380.55%
Apr 25	-407.34%
Apr 25	-430.46%
Mar 25	-339.99%
Mar 25	-308.36%
Mar 25	-360.46%
Mar 25	-372.34%
Feb 25	-409.23%
Feb 25	-380.31%
Feb 25	-407.35%
Feb 25	-394.68%
Jan 25	-471.1%
Jan 25	-457.74%
Jan 25	-485.92%
Jan 25	-419.37%
Jan 25	-342.87%
Dec 24	-383.6%
Dec 24	-503.84%
Dec 24	-455.4%
Dec 24	-85.18%
Nov 24	-76.89%
Nov 24	-74.94%
Nov 24	-488.57%
Nov 24	-428.65%
Nov 24	-447.66%
Oct 24	-66.2%
Oct 24	-64.3%

Price to Book

CLRB Price to Book by year
Period	Price to Book
Sep 26	0.95
Sep 26	0.97
Aug 26	1.04
Aug 26	1.06
Aug 26	1.06
Aug 26	2.31
Jul 26	2.31
Jul 26	2.17
Jul 26	2.26
Jul 26	2.53
Jul 26	2.53
Jun 26	2.27
Jun 26	2.51
Jun 26	2
Jun 26	2.33
May 26	2.82
May 26	2.88
May 26	2.78
May 26	1.33
May 26	1.15
Apr 26	1.18
Apr 26	1.25
Apr 26	1.18
Apr 26	1.09
Mar 26	1.15
Mar 26	1.38
Mar 26	1.37
Mar 26	1.18
Feb 26	1.1
Feb 26	1.14
Feb 26	1.11
Feb 26	1.02
Jan 26	1.09
Jan 26	1.28
Jan 26	1.21
Jan 26	1.04
Jan 26	1.17
Dec 25	0.86
Dec 25	0.9
Dec 25	1.22
Dec 25	1.27
Nov 25	1.21
Nov 25	0.96
Nov 25	0.98
Nov 25	0.73
Oct 25	0.73
Oct 25	0.86
Oct 25	0.97
Oct 25	1
Oct 25	1.25
Sep 25	1.19
Sep 25	1.12
Sep 25	1.09
Sep 25	1.07
Aug 25	1.05
Aug 25	1.05
Aug 25	0.94
Aug 25	0.88
Aug 25	0.88
Jul 25	0.95
Jul 25	0.93
Jul 25	0.91
Jul 25	0.89
Jun 25	1.47
Jun 25	1.63
Jun 25	2.31
Jun 25	2.01
May 25	1.42
May 25	1.39
May 25	1.37
May 25	0.73
May 25	0.79
Apr 25	0.91
Apr 25	0.88
Apr 25	0.82
Apr 25	0.77
Mar 25	0.98
Mar 25	1.08
Mar 25	0.93
Mar 25	0.82
Feb 25	0.75
Feb 25	0.81
Feb 25	0.75
Feb 25	0.78
Jan 25	0.65
Jan 25	0.67
Jan 25	0.63
Jan 25	0.73
Jan 25	0.9
Dec 24	0.8
Dec 24	0.61
Dec 24	0.67
Dec 24	3.61
Nov 24	3.99
Nov 24	4.1
Nov 24	0.69
Nov 24	0.78
Nov 24	0.75
Oct 24	4.29
Oct 24	4.42

No video analysis for this stock yet. Request one from our team.

News: CLRB

seekingalpha.com · 18 Aug 2026

Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript

seekingalpha.com · 13 Aug 2026

Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript

globenewswire.com · 13 Aug 2026

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program

defenseworld.net · 11 Aug 2026

Analysts Set Cellectar Biosciences, Inc. (NASDAQ:CLRB) PT at $11.00

Cellectar Biosciences, Inc. (NASDAQ: CLRB - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on

globenewswire.com · 30 Jul 2026

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m.

globenewswire.com · 15 Jul 2026

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma